hydralazine has been researched along with Pulmonary Hypertension in 83 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A two-year-old child dying of pulmonary hypertension and cor pulmonale secondary to bronchopulmonary dysplasia, was demonstrated to have reactive pulmonary hypertension in response to 100% oxygen and isoproterenol infusion." | 9.06 | Treatment of pulmonary hypertension with diltiazem in a child with bronchopulmonary dysplasia. ( Bingham, WT; Duncan, WJ; Kasian, GF; Mersal, A; Ninan, A; Sankaran, K; Tyrrell, MJ, 1988) |
| "The acute hemodynamic effects of both sublingual nifedipine (N) and intravenous hydralazine (Hy) were studied in 5 patients with primary pulmonary hypertension to ascertain whether the capacity for pulmonary vasodilatation was generalized or drug-specific, and to determine which of the 2 agents had preferential pulmonary vasodilatory effects." | 7.67 | Hemodynamic effects of nifedipine versus hydralazine in primary pulmonary hypertension. ( Borer, JS; Fisher, J; Goldberg, HL; Mermelstein, M; Moses, JW; Niarchos, AP; Whitman, HH, 1984) |
| "Reports on hemodynamic effects of hydralazine on pulmonary hypertension (primary or secondary) usually include cases with severe disease or with mixed varieties of pulmonary vascular disease." | 7.67 | Effects of hydralazine on hemodynamics, ventilation, and gas exchange in patients with chronic obstructive pulmonary disease and pulmonary hypertension. ( Chun, DS; Dolan, GF; Keller, CA; Minh, VD; Shepard, JW; Vasquez, P, 1984) |
| "Administration of hydralazine in patients with pulmonary hypertension has been reported to cause excessive systemic vasodilatation, limiting its clinical utility (N Engl J Med 1982; 306: 1326)." | 7.67 | Continuous, low dose of hydralazine, reduces acute hypoxic pulmonary hypertension without a corresponding fall in systemic arterial pressure. ( Kobayashi, T; Yoshimura, K, 1986) |
| "Hydralazine has been shown to increase minute ventilation, alveolar ventilation, and arterial partial pressure of oxygen (PaO2) after short-term administration in patients with chronic obstructive pulmonary disease and pulmonary hypertension." | 7.67 | Long-term effects of hydralazine on ventilation and blood gas values in patients with chronic obstructive pulmonary disease and pulmonary hypertension. ( Corriveau, ML; Dolan, GF, 1987) |
| "Hydralazine has been shown to increase minute ventilation (VE) in patients with chronic obstructive pulmonary disease and pulmonary hypertension." | 7.67 | Effects of hydralazine on mouth occlusion pressure and ventilatory response to hypercapnia in patients with chronic obstructive pulmonary disease and pulmonary hypertension. ( Corriveau, ML; Dolan, GF; Shepard, JW, 1987) |
| "Hydralazine was administered short-term to 13 patients who had stable interstitial lung disease (ILD), pulmonary arterial hypertension (PAH); mean pulmonary arterial pressure ( [PAP]=26 +/- 9 mm Hg), and cor pulmonale (CP)." | 7.67 | Hemodynamic effect of hydralazine in interstitial lung disease patients with cor pulmonale. Immediate and short-term evaluation at rest and during exercise. ( Barrios, R; Gomez, A; Lupi-Herrera, E; Martinez, W; Sandoval, J; Seoane, M; Verdejo, J, 1985) |
| "A patient who developed pulmonary hypertension and systemic lupus erythematosus as a complication of hydralazine therapy is reported." | 7.67 | Pulmonary hypertension in hydralazine induced systemic lupus erythematosus: association with C4 null allele. ( Asherson, RA; Benbow, AG; Hughes, GR; Jackson, N; Speirs, CJ, 1986) |
| "30 mg/kg) doses of intravenous hydralazine was evaluated in 26 consecutive patients with severe pulmonary hypertension due to cor pulmonale (nine patients), primary pulmonary hypertension (11 patients), or pulmonary embolism (six patients)." | 7.66 | Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension. ( Choo, MH; McGoon, MD; Moyer, TP; Reeder, GS; Seward, JB; Vlietstra, RE, 1983) |
| "Thirteen consecutive patients with primary and secondary pulmonary hypertension who had normal left ventricular function were treated with hydralazine in an effort to reduce pulmonary vascular resistance and clinical symptoms." | 7.66 | Deleterious effects of hydralazine in patients with pulmonary hypertension. ( Dash, H; Greenberg, B; Massie, B; Packer, M, 1982) |
| "To evaluate the hemodynamic effects of hydralazine in four patients with primary pulmonary hypertension, we catheterized the right side of the heart before and 48 hours after starting therapy with oral hydralazine, 50 mg every six hours." | 7.66 | Oral hydralazine therapy for primary pulmonary hypertension. ( Peter, RH; Rubin, LJ, 1980) |
| "Progressive dyspnea and syncope occurred in a young woman with primary pulmonary hypertension despite therapy with hydralazine." | 7.66 | Hemodynamic effects of nifedipine in primary pulmonary hypertension. ( Douglas, JS, 1983) |
| "The effects of 3 types of vasoactive agents, hydralazine, nifedipine and amrinone, were evaluated in 7 patients with primary pulmonary hypertension (PPH)." | 7.66 | Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertension. ( Ganz, R; Levy, PS; Rich, S, 1983) |
| "Thirteen patients with severe hypertension were treated with combined minoxidil, propranolol, and furosemide (mean daily doses 33 mg, 475 mg, and 578 mg, respectively) for nine to twenty-five months (mean 13." | 7.65 | Long-term treatment of severe hypertension with minoxidil, propranolol and furosemide. ( Bennet, CM; Blaufuss, A; Wilburn, RL, 1975) |
| "Urapidil is a new vasodilator that acts by postsynaptic alpha 1-blockade while inhibiting the aortic pressure baroreceptor reflex and reducing central sympathetic tone." | 6.66 | Hemodynamic effects of urapidil in patients with pulmonary hypertension. A comparative study with hydralazine. ( Abrouk, F; Adnot, S; Brun-Buisson, C; Defouilloy, C; Lemaire, F; Piquet, J, 1987) |
| "Pulmonary hypertension was produced in sheep by the continuous administration of the thromboxane A2-mimetic U46619." | 5.28 | Effects of prostaglandin E1 and hydralazine on the longitudinal distribution of pulmonary vascular resistance during vasoconstrictor pulmonary hypertension in sheep. ( Pearl, RG; Siegel, LC, 1992) |
| "Hydralazine has been employed as a test drug, but because of its long duration of action there is a risk of sustained systemic arterial hypotension in patients with a fixed pulmonary vascular resistance." | 5.27 | A comparison of the acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension. ( Cato, AE; Frosolono, MF; Groves, BM; Reeves, JT; Rubin, LJ, 1985) |
| "A two-year-old child dying of pulmonary hypertension and cor pulmonale secondary to bronchopulmonary dysplasia, was demonstrated to have reactive pulmonary hypertension in response to 100% oxygen and isoproterenol infusion." | 5.06 | Treatment of pulmonary hypertension with diltiazem in a child with bronchopulmonary dysplasia. ( Bingham, WT; Duncan, WJ; Kasian, GF; Mersal, A; Ninan, A; Sankaran, K; Tyrrell, MJ, 1988) |
| "The acute hemodynamic effects of both sublingual nifedipine (N) and intravenous hydralazine (Hy) were studied in 5 patients with primary pulmonary hypertension to ascertain whether the capacity for pulmonary vasodilatation was generalized or drug-specific, and to determine which of the 2 agents had preferential pulmonary vasodilatory effects." | 3.67 | Hemodynamic effects of nifedipine versus hydralazine in primary pulmonary hypertension. ( Borer, JS; Fisher, J; Goldberg, HL; Mermelstein, M; Moses, JW; Niarchos, AP; Whitman, HH, 1984) |
| "Reports on hemodynamic effects of hydralazine on pulmonary hypertension (primary or secondary) usually include cases with severe disease or with mixed varieties of pulmonary vascular disease." | 3.67 | Effects of hydralazine on hemodynamics, ventilation, and gas exchange in patients with chronic obstructive pulmonary disease and pulmonary hypertension. ( Chun, DS; Dolan, GF; Keller, CA; Minh, VD; Shepard, JW; Vasquez, P, 1984) |
| "The hemodynamic and clinical responses to calcium channel blockade with verapamil and nifedipine were compared with those of hydralazine in 12 patients with pulmonary hypertension secondary to obliterative pulmonary vascular disease." | 3.67 | Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. ( Medina, N; Packer, M; Yushak, M, 1984) |
| "Hydralazine has been shown to increase minute ventilation, alveolar ventilation, and arterial partial pressure of oxygen (PaO2) after short-term administration in patients with chronic obstructive pulmonary disease and pulmonary hypertension." | 3.67 | Long-term effects of hydralazine on ventilation and blood gas values in patients with chronic obstructive pulmonary disease and pulmonary hypertension. ( Corriveau, ML; Dolan, GF, 1987) |
| " Because Indo may interfere with the hypotensive effect of hydralazine and because hydralazine has been proposed in the treatment of patients with pulmonary hypertension, 7 of these patients also received 0." | 3.67 | Effects of indomethacin on pulmonary hemodynamics and gas exchange in patients with pulmonary artery hypertension, interference with hydralazine. ( Adnot, S; Brun-Buisson, C; de Cremoux, H; Defouilloy, C; Lemaire, F; Piquet, J, 1987) |
| "Hydralazine has been shown to increase minute ventilation (VE) in patients with chronic obstructive pulmonary disease and pulmonary hypertension." | 3.67 | Effects of hydralazine on mouth occlusion pressure and ventilatory response to hypercapnia in patients with chronic obstructive pulmonary disease and pulmonary hypertension. ( Corriveau, ML; Dolan, GF; Shepard, JW, 1987) |
| "Administration of hydralazine in patients with pulmonary hypertension has been reported to cause excessive systemic vasodilatation, limiting its clinical utility (N Engl J Med 1982; 306: 1326)." | 3.67 | Continuous, low dose of hydralazine, reduces acute hypoxic pulmonary hypertension without a corresponding fall in systemic arterial pressure. ( Kobayashi, T; Yoshimura, K, 1986) |
| "Hydralazine was administered short-term to 13 patients who had stable interstitial lung disease (ILD), pulmonary arterial hypertension (PAH); mean pulmonary arterial pressure ( [PAP]=26 +/- 9 mm Hg), and cor pulmonale (CP)." | 3.67 | Hemodynamic effect of hydralazine in interstitial lung disease patients with cor pulmonale. Immediate and short-term evaluation at rest and during exercise. ( Barrios, R; Gomez, A; Lupi-Herrera, E; Martinez, W; Sandoval, J; Seoane, M; Verdejo, J, 1985) |
| "A patient who developed pulmonary hypertension and systemic lupus erythematosus as a complication of hydralazine therapy is reported." | 3.67 | Pulmonary hypertension in hydralazine induced systemic lupus erythematosus: association with C4 null allele. ( Asherson, RA; Benbow, AG; Hughes, GR; Jackson, N; Speirs, CJ, 1986) |
| "30 mg/kg) doses of intravenous hydralazine was evaluated in 26 consecutive patients with severe pulmonary hypertension due to cor pulmonale (nine patients), primary pulmonary hypertension (11 patients), or pulmonary embolism (six patients)." | 3.66 | Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension. ( Choo, MH; McGoon, MD; Moyer, TP; Reeder, GS; Seward, JB; Vlietstra, RE, 1983) |
| "Progressive dyspnea and syncope occurred in a young woman with primary pulmonary hypertension despite therapy with hydralazine." | 3.66 | Hemodynamic effects of nifedipine in primary pulmonary hypertension. ( Douglas, JS, 1983) |
| "The effects of 3 types of vasoactive agents, hydralazine, nifedipine and amrinone, were evaluated in 7 patients with primary pulmonary hypertension (PPH)." | 3.66 | Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertension. ( Ganz, R; Levy, PS; Rich, S, 1983) |
| "Thirteen consecutive patients with primary and secondary pulmonary hypertension who had normal left ventricular function were treated with hydralazine in an effort to reduce pulmonary vascular resistance and clinical symptoms." | 3.66 | Deleterious effects of hydralazine in patients with pulmonary hypertension. ( Dash, H; Greenberg, B; Massie, B; Packer, M, 1982) |
| "Hydralazine reduces pulmonary vascular resistance in patients with primary and secondary pulmonary hypertension, but the effects on right ventricular function of a change in resistance without a reduction in pulmonary arterial pressure are not known." | 3.66 | The effects of oral hydralazine on right ventricular end-diastolic pressure in patients with right ventricular failure. ( Handel, F; Peter, RH; Rubin, LJ, 1982) |
| "To evaluate the hemodynamic effects of hydralazine in four patients with primary pulmonary hypertension, we catheterized the right side of the heart before and 48 hours after starting therapy with oral hydralazine, 50 mg every six hours." | 3.66 | Oral hydralazine therapy for primary pulmonary hypertension. ( Peter, RH; Rubin, LJ, 1980) |
| "Thirteen patients with severe hypertension were treated with combined minoxidil, propranolol, and furosemide (mean daily doses 33 mg, 475 mg, and 578 mg, respectively) for nine to twenty-five months (mean 13." | 3.65 | Long-term treatment of severe hypertension with minoxidil, propranolol and furosemide. ( Bennet, CM; Blaufuss, A; Wilburn, RL, 1975) |
| "Urapidil is a new vasodilator that acts by postsynaptic alpha 1-blockade while inhibiting the aortic pressure baroreceptor reflex and reducing central sympathetic tone." | 2.66 | Hemodynamic effects of urapidil in patients with pulmonary hypertension. A comparative study with hydralazine. ( Abrouk, F; Adnot, S; Brun-Buisson, C; Defouilloy, C; Lemaire, F; Piquet, J, 1987) |
| "Hydralazine was the only drug that significantly increased cardiac output (1." | 1.28 | Vasodilator therapy in microembolic porcine pulmonary hypertension. ( McLean, RF; Pearl, RG; Prielipp, RC; Rosenthal, MH, 1990) |
| "Thus, in this canine model of acute pulmonary embolism: 1) VA/Q distributions were moderately impaired accounting for only slight hypoxemia, and 2) pulmonary hypertension was partially reversible by hydralazine and by nitroprusside without associated non-flow-dependent change in VA/Q distributions and arterial oxygenation." | 1.28 | Effects of vasodilators on gas exchange in acute canine embolic pulmonary hypertension. ( Delcroix, M; Leeman, M; Lejeune, P; Mélot, C; Naeije, R, 1990) |
| "Pulmonary hypertension was produced in sheep by the continuous administration of the thromboxane A2-mimetic U46619." | 1.28 | Effects of prostaglandin E1 and hydralazine on the longitudinal distribution of pulmonary vascular resistance during vasoconstrictor pulmonary hypertension in sheep. ( Pearl, RG; Siegel, LC, 1992) |
| "Hydralazine was administered in a dose sufficient to double CO." | 1.27 | Pulmonary vascular effects of hydralazine in a canine preparation of pulmonary thromboembolism. ( Ducas, J; Girling, L; Prewitt, RM; Schick, U, 1986) |
| "A 23-year-old woman with systemic lupus erythematosus was found to have severe pulmonary hypertension with secondary patency of the foramen ovale." | 1.27 | Danger of vasodilator therapy for pulmonary hypertension in patent foramen ovale. ( Girard, P; Laine, JF; Motté, G; Petitpretz, P; Slama, M, 1986) |
| "Hydralazine has been employed as a test drug, but because of its long duration of action there is a risk of sustained systemic arterial hypotension in patients with a fixed pulmonary vascular resistance." | 1.27 | A comparison of the acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension. ( Cato, AE; Frosolono, MF; Groves, BM; Reeves, JT; Rubin, LJ, 1985) |
| "Hydralazine was administered acutely to 12 patients who had pulmonary arterial hypertension of unknown cause." | 1.26 | The role of hydralazine therapy for pulmonary arterial hypertension of unknown cause. ( Bialostozky, D; Lupi-Herrera, E; Sandoval, J; Seoane, M, 1982) |
| "Isosorbide dinitrate was the only drug that elicited any reduction in pulmonary artery pressure; pulmonary vascular resistance decreased modestly." | 1.26 | Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension. ( Bambach, D; Fontana, ME; Hermiller, JB; Huss, P; Leier, CV; Magorien, RD; Thompson, MJ; Unverferth, DV, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 70 (84.34) | 18.7374 |
| 1990's | 12 (14.46) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (1.20) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, CM | 1 |
| Preston, IR | 1 |
| Hill, NS | 1 |
| Suzuki, YJ | 1 |
| Tuxen, DV | 1 |
| Powles, AC | 1 |
| Mathur, PN | 1 |
| Pugsley, SO | 1 |
| Campbell, EJ | 1 |
| Rubin, LJ | 8 |
| Dubiel, JP | 1 |
| Pyzik, Z | 1 |
| Brzostek, T | 1 |
| Kolasińska-Kloch, W | 1 |
| Peter, RH | 4 |
| Rubin, L | 1 |
| Brent, BN | 2 |
| Berger, HJ | 2 |
| Matthay, RA | 2 |
| Mahler, D | 1 |
| Pytlik, L | 1 |
| Zaret, BL | 2 |
| Fisher, J | 1 |
| Borer, JS | 1 |
| Moses, JW | 1 |
| Goldberg, HL | 1 |
| Niarchos, AP | 1 |
| Whitman, HH | 1 |
| Mermelstein, M | 1 |
| Keller, CA | 2 |
| Shepard, JW | 2 |
| Chun, DS | 2 |
| Dolan, GF | 4 |
| Vasquez, P | 1 |
| Minh, VD | 1 |
| Packer, M | 2 |
| Medina, N | 1 |
| Yushak, M | 1 |
| Cordasco, EM | 1 |
| Rich, S | 5 |
| Ganz, R | 1 |
| Levy, PS | 4 |
| McGoon, MD | 1 |
| Seward, JB | 1 |
| Vlietstra, RE | 1 |
| Choo, MH | 1 |
| Moyer, TP | 1 |
| Reeder, GS | 1 |
| Rüegger, M | 1 |
| Medici, TC | 1 |
| Cotter, L | 1 |
| Mahler, DA | 1 |
| Lister, G | 1 |
| Stanbrook, HS | 1 |
| Morris, KG | 1 |
| McMurtry, IF | 1 |
| Pannarale, G | 2 |
| Gaspardone, A | 2 |
| Acconcia, MC | 2 |
| Valente, A | 2 |
| Martinez, J | 1 |
| Lam, W | 1 |
| Rosen, KM | 1 |
| Douglas, JS | 1 |
| Lupi-Herrera, E | 2 |
| Sandoval, J | 3 |
| Seoane, M | 2 |
| Bialostozky, D | 1 |
| Fishman, AP | 2 |
| Greenberg, B | 1 |
| Massie, B | 1 |
| Dash, H | 1 |
| Kadowitz, PJ | 1 |
| Hyman, AL | 1 |
| Handel, F | 1 |
| Kronzon, I | 1 |
| Cohen, M | 1 |
| Winer, HE | 1 |
| Moser, KM | 1 |
| McWeeney, J | 1 |
| Finnegan, P | 1 |
| Hermiller, JB | 1 |
| Bambach, D | 1 |
| Thompson, MJ | 1 |
| Huss, P | 1 |
| Fontana, ME | 1 |
| Magorien, RD | 1 |
| Unverferth, DV | 1 |
| Leier, CV | 1 |
| Farber, H | 1 |
| Glauser, FL | 1 |
| Fripp, RR | 1 |
| Gewitz, MH | 1 |
| Werner, JC | 1 |
| Whitman, V | 1 |
| Rashkind, WJ | 1 |
| Das, UN | 1 |
| Reeves, JT | 2 |
| Santini, D | 1 |
| Fox, D | 1 |
| Kloner, RA | 1 |
| Konstam, M | 1 |
| Rude, RE | 1 |
| Lorell, BH | 1 |
| Elkayam, U | 1 |
| Volkova, LI | 1 |
| Shteĭngart, IuN | 1 |
| Gavaghan, BJ | 1 |
| Lapointe, JM | 1 |
| Thomas, WP | 1 |
| Collados, MT | 1 |
| López, S | 1 |
| Massó, FA | 1 |
| Páez, A | 1 |
| Borbolla, JR | 1 |
| Montaño, LF | 1 |
| Fleischmann, LE | 1 |
| Wilburn, RL | 1 |
| Blaufuss, A | 1 |
| Bennet, CM | 1 |
| Friedman, DM | 1 |
| Mitnick, HJ | 1 |
| Danilowicz, D | 1 |
| Priebe, HJ | 2 |
| Vorob'ev, LP | 1 |
| Maev, IV | 1 |
| Pearl, RG | 3 |
| Siegel, LC | 1 |
| Lewczuk, J | 1 |
| Wrabec, K | 1 |
| Martin, GR | 1 |
| Chauvin, L | 1 |
| Short, BL | 1 |
| Phlippoteau, C | 1 |
| Brenot, F | 1 |
| Blétry, O | 1 |
| Simmonneau, G | 1 |
| Duroux, P | 1 |
| McLean, RF | 1 |
| Prielipp, RC | 2 |
| Rosenthal, MH | 2 |
| Delcroix, M | 1 |
| Mélot, C | 1 |
| Lejeune, P | 1 |
| Leeman, M | 1 |
| Naeije, R | 1 |
| Mazza, F | 1 |
| Morra, AM | 1 |
| Morra, MG | 1 |
| Catalano, M | 1 |
| Contiello, V | 1 |
| Polcino, A | 1 |
| Palevsky, HI | 1 |
| Hughes, JD | 1 |
| Hammond, TG | 1 |
| Mosesson, MW | 1 |
| Sun, BT | 1 |
| Corriveau, ML | 3 |
| Rosen, BJ | 1 |
| Goodman, G | 1 |
| Perkin, RM | 1 |
| Anas, NG | 1 |
| Sperling, DR | 1 |
| Hicks, DA | 1 |
| Rowen, M | 1 |
| Kasian, GF | 1 |
| Ninan, A | 1 |
| Duncan, WJ | 1 |
| Bingham, WT | 1 |
| Mersal, A | 1 |
| Tyrrell, MJ | 1 |
| Sankaran, K | 1 |
| Adnot, S | 3 |
| Defouilloy, C | 3 |
| Abrouk, F | 2 |
| Kouzan, S | 1 |
| Lemaire, F | 3 |
| Halpern, SM | 1 |
| Shah, PK | 1 |
| Lehrman, S | 1 |
| Goldberg, HS | 1 |
| Jasper, AC | 1 |
| Koerner, SK | 1 |
| Brun-Buisson, C | 2 |
| Piquet, J | 2 |
| de Cremoux, H | 1 |
| Ducas, J | 1 |
| Girling, L | 1 |
| Schick, U | 1 |
| Prewitt, RM | 1 |
| Laine, JF | 1 |
| Slama, M | 1 |
| Petitpretz, P | 1 |
| Girard, P | 1 |
| Motté, G | 1 |
| Cernohorský, D | 1 |
| Král, B | 1 |
| Hamet, A | 1 |
| Eliás, J | 1 |
| Tilser, P | 1 |
| Rozánek, P | 1 |
| Sramar, V | 1 |
| Koudelka, V | 1 |
| Asherson, RA | 1 |
| Benbow, AG | 1 |
| Speirs, CJ | 1 |
| Jackson, N | 1 |
| Hughes, GR | 1 |
| Yoshimura, K | 1 |
| Kobayashi, T | 1 |
| Groves, BM | 1 |
| Frosolono, MF | 1 |
| Cato, AE | 1 |
| Dal Nogare, AR | 1 |
| D'Alonzo, GE | 1 |
| Dantzker, DR | 1 |
| Cerdá, E | 1 |
| Esteban, A | 1 |
| de la Cal, MA | 1 |
| Fernández, A | 1 |
| García, A | 1 |
| Verdejo, J | 1 |
| Gomez, A | 1 |
| Barrios, R | 1 |
| Martinez, W | 1 |
| Brundage, BH | 1 |
| Gladman, DD | 1 |
| Sternberg, L | 1 |
| Ohar, J | 1 |
| Polatty, C | 1 |
| Robichaud, A | 1 |
| Fowler, A | 1 |
| Vetrovec, G | 1 |
| Glauser, F | 1 |
6 reviews available for hydralazine and Pulmonary Hypertension
| Article | Year |
|---|---|
Cardiovascular effects of vasodilator therapy for pulmonary arterial hypertension.
Topics: Cardiac Output; Echocardiography; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Hypote | 1983 |
The pharmacologic control of the pulmonary circulation in pulmonary hypertension.
Topics: Acetylcholine; Adult; Aminophylline; Calcium Channel Blockers; Diazoxide; Female; Humans; Hydralazin | 1984 |
[Early pulmonary hypertension: current therapeutic prospectives].
Topics: Calcium Channel Blockers; Captopril; Diazoxide; Diltiazem; Humans; Hydralazine; Hypertension, Pulmon | 1982 |
[Value of vasodilator agents in the treatment of diseases with pulmonary hypertension caused by chronic obstructive lung diseases].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 1991 |
Vasodilator therapy for primary pulmonary hypertension.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Calcium Channel Blockers; Hum | 1985 |
Primary pulmonary hypertension. An analysis of 28 cases and a review of the literature.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aminorex; Anticoagulants; Autoimmune Diseases; Calc | 1986 |
5 trials available for hydralazine and Pulmonary Hypertension
| Article | Year |
|---|---|
[Treatment of primary pulmonary hypertension with hydralazine].
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Female; Humans; Hydralazine; Hypertension, Pulmonar | 1983 |
Characterization of von Willebrand factor in primary pulmonary hypertension.
Topics: Adrenergic beta-Agonists; Adult; Antigens; Biomarkers; Blotting, Western; Calcium Channel Blockers; | 1999 |
[Effects of corinfar, nitrosorbide and apressin on external respiration and blood flow in chronic obstructive bronchitis].
Topics: Blood Circulation; Bronchitis; Humans; Hydralazine; Hypertension, Pulmonary; Isosorbide Dinitrate; N | 1992 |
Treatment of pulmonary hypertension with diltiazem in a child with bronchopulmonary dysplasia.
Topics: Albuterol; Bronchopulmonary Dysplasia; Child, Preschool; Diltiazem; Humans; Hydralazine; Hypertensio | 1988 |
Hemodynamic effects of urapidil in patients with pulmonary hypertension. A comparative study with hydralazine.
Topics: Aged; Blood Pressure; Cardiac Output; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmo | 1987 |
72 other studies available for hydralazine and Pulmonary Hypertension
| Article | Year |
|---|---|
Iron chelation inhibits the development of pulmonary vascular remodeling.
Topics: Animals; Blood Proteins; Case-Control Studies; Cell Proliferation; Cells, Cultured; Deferoxamine; Fe | 2012 |
Detrimental effects of hydralazine in patients with chronic air-flow obstruction and pulmonary hypertension. A combined hemodynamic and radionuclide study.
Topics: Aged; Angiography; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Lung Diseases | 1984 |
Contrasting acute effects of vasodilators (nitroglycerin, nitroprusside, and hydralazine) on right ventricular performance in patients with chronic obstructive pulmonary disease and pulmonary hypertension: a combined radionuclide-hemodynamic study.
Topics: Adult; Aged; Female; Heart; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Lung Disease | 1983 |
Hemodynamic effects of nifedipine versus hydralazine in primary pulmonary hypertension.
Topics: Blood Pressure; Cardiac Output; Heart Rate; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmona | 1984 |
Effects of hydralazine on hemodynamics, ventilation, and gas exchange in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
Topics: Drug Tolerance; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Lung Diseases, Obstructi | 1984 |
Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease.
Topics: Adult; Calcium Channel Blockers; Cardiac Output; Exercise Test; Female; Hemodynamics; Humans; Hydral | 1984 |
Pulmonary vascular disease--overview.
Topics: Angiography; Heparin; Humans; Hydralazine; Hypertension, Pulmonary; Lung; Lung Diseases, Obstructive | 1983 |
Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertension.
Topics: Adult; Aminopyridines; Amrinone; Cardiac Catheterization; Cardiac Output; Female; Humans; Hydralazin | 1983 |
Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension.
Topics: Adolescent; Adult; Aged; Blood Pressure; Female; Follow-Up Studies; Hemodynamics; Humans; Hydralazin | 1983 |
[New therapies for cor pulmonale?].
Topics: Bloodletting; Humans; Hydralazine; Hypertension, Pulmonary; Hypoxia; Iron; Lung Diseases, Obstructiv | 1983 |
Vasodilator treatment of primary pulmonary hypertension.
Topics: Administration, Oral; Adult; Diazoxide; Female; Humans; Hydralazine; Hypertension, Pulmonary; Middle | 1984 |
Relationship between oxygen uptake and oxygen transport in stable patients with chronic obstructive pulmonary disease. Physiologic effects of nitroprusside and hydralazine.
Topics: Aged; Biological Transport; Ferricyanides; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonar | 1984 |
Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists.
Topics: Animals; Dimethyl Sulfoxide; Hydralazine; Hypertension, Pulmonary; Hypoxia; Male; Nifedipine; Pulmon | 1984 |
Reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: guidelines for determining a pulmonary vasodilator response.
Topics: Adult; Blood Pressure; Cardiac Catheterization; Cardiac Output; Diazoxide; Female; Humans; Hydralazi | 1983 |
Hemodynamic effects of nifedipine in primary pulmonary hypertension.
Topics: Adult; Exercise Test; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Nifedipine | 1983 |
[Primary pulmonary hypertension: current therapeutic prospectives].
Topics: Calcium Channel Blockers; Diazoxide; Heart Rate; Humans; Hydralazine; Hypertension, Pulmonary; Isopr | 1982 |
The role of hydralazine therapy for pulmonary arterial hypertension of unknown cause.
Topics: Administration, Oral; Adolescent; Adult; Child; Female; Follow-Up Studies; Hemodynamics; Humans; Hyd | 1982 |
Unexplained pulmonary hypertension.
Topics: Humans; Hydralazine; Hypertension, Pulmonary; Pulmonary Circulation | 1982 |
Deleterious effects of hydralazine in patients with pulmonary hypertension.
Topics: Adult; Aged; Blood Pressure; Drug Evaluation; Female; Heart Rate; Humans; Hydralazine; Hypertension, | 1982 |
Hydralazine and the treatment of primary pulmonary hypertension.
Topics: Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary | 1982 |
The effects of oral hydralazine on right ventricular end-diastolic pressure in patients with right ventricular failure.
Topics: Adult; Aged; Arterioles; Blood Pressure; Cardiac Output; Female; Heart Failure; Humans; Hydralazine; | 1982 |
Adverse effect of hydralazine in patients with primary pulmonary hypertension.
Topics: Administration, Oral; Adult; Blood Pressure; Cardiac Output; Female; Humans; Hydralazine; Hypertensi | 1982 |
Idiopathic pulmonary hypertension: therapeutic opportunities and pitfalls.
Topics: Diagnosis, Differential; Humans; Hydralazine; Hypertension, Pulmonary; Risk; Vascular Resistance | 1982 |
Vasodilator therapy of pulmonary hypertension in the CRST syndrome.
Topics: Calcinosis; Female; Humans; Hydralazine; Hypertension, Pulmonary; Male; Middle Aged; Raynaud Disease | 1982 |
Hydralazine in pulmonary hypertension.
Topics: Humans; Hydralazine; Hypertension, Pulmonary; Lung Diseases, Obstructive; Nifedipine | 1982 |
Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension.
Topics: Adolescent; Adult; Aspirin; Diazoxide; Dipyridamole; Female; Hemodynamics; Humans; Hydralazine; Hype | 1982 |
The effect of oral hydralazine on the pulmonary hemodynamics of patients with pulmonary foreign body granulomatosis.
Topics: Administration, Oral; Adult; Dyspnea; Granuloma; Hemodynamics; Humans; Hydralazine; Hypertension, Pu | 1982 |
Oral hydralazine in patients with pulmonary vascular disease secondary to congenital heart disease.
Topics: Administration, Oral; Cardiac Output; Child; Child, Preschool; Female; Heart Defects, Congenital; He | 1981 |
Prostaglandins and pulmonary hypertension-further evidence.
Topics: Humans; Hydralazine; Hypertension, Pulmonary; Prostaglandins; Pulmonary Circulation; Regional Blood | 1981 |
Hope in primary pulmonary hypertension.
Topics: Child; Diazoxide; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Pregnancy; Tim | 1980 |
Oral hydralazine therapy for primary pulmonary hypertension.
Topics: Administration, Oral; Adult; Blood Pressure; Cardiac Catheterization; Cardiac Output; Female; Heart | 1980 |
Vasodilator therapy for pulmonary hypertension.
Topics: Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary | 1980 |
Primary pulmonary hypertension: new approaches to therapy.
Topics: Diazoxide; Female; Humans; Hydralazine; Hypertension, Pulmonary; Phentolamine; Pregnancy | 1980 |
Pulmonary hypertension in systemic lupus erythematosus: hemodynamics and effects of vasodilator therapy.
Topics: Adult; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Lupus Erythematosus, Syst | 1980 |
Vasodilator therapy in primary pulmonary hypertension.
Topics: Adult; Diazoxide; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Isoproterenol; | 1981 |
[Individual approach to vasodilator treatment of pulmonary hypertension in chronic bronchitis].
Topics: Adult; Aminophylline; Bronchitis; Chronic Disease; Humans; Hydralazine; Hypertension, Pulmonary; Mid | 1994 |
Acute onset of pulmonary necrotising arteritis in a dog with a left-to-right patent ductus arteriosus.
Topics: Acute Disease; Animals; Antihypertensive Agents; Dog Diseases; Dogs; Ductus Arteriosus, Patent; Echo | 1998 |
Management of hypertensive crisis in children.
Topics: Acute Disease; Adolescent; Cerebrovascular Disorders; Child; Child, Preschool; Diazoxide; Humans; Hy | 1977 |
Long-term treatment of severe hypertension with minoxidil, propranolol and furosemide.
Topics: Cardiac Catheterization; Drug Therapy, Combination; Echocardiography; Edema; Furosemide; Humans; Hyd | 1975 |
Recovery from pulmonary hypertension in an adolescent with mixed connective tissue disease.
Topics: Child; Cyclophosphamide; Female; Humans; Hydralazine; Hypertension, Pulmonary; Mixed Connective Tiss | 1992 |
Myocardial ischemia during vasodilator therapy in a canine model of pulmonary hypertension and coronary insufficiency.
Topics: Alprostadil; Animals; Coronary Disease; Coronary Vessels; Dogs; Hemodynamics; Hydralazine; Hypertens | 1992 |
Effects of prostaglandin E1 and hydralazine on the longitudinal distribution of pulmonary vascular resistance during vasoconstrictor pulmonary hypertension in sheep.
Topics: Alprostadil; Animals; Hydralazine; Hypertension, Pulmonary; Lung; Male; Prostaglandin Endoperoxides, | 1992 |
Effects of hydralazine on cardiac performance in infants receiving extracorporeal membrane oxygenation.
Topics: Blood Flow Velocity; Cardiac Output; Cerebrovascular Circulation; Extracorporeal Membrane Oxygenatio | 1991 |
[Vasodilator agents in pulmonary artery hypertension of systemic scleroderma].
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Epoprostenol; Female; Humans; Hydralazine; Hypertension | 1990 |
Vasodilator therapy in microembolic porcine pulmonary hypertension.
Topics: Alprostadil; Animals; Ferricyanides; Hemodynamics; Hydralazine; Hypertension, Pulmonary; Infusions, | 1990 |
Effects of vasodilators on gas exchange in acute canine embolic pulmonary hypertension.
Topics: Acute Disease; Alprostadil; Animals; Dogs; Hydralazine; Hypertension, Pulmonary; Nitroprusside; Pulm | 1990 |
[Primary pulmonary hypertension: physiopathology and critical evaluation of the therapy].
Topics: Blood Pressure; Captopril; Drug Evaluation; Epoprostenol; Humans; Hydralazine; Hypertension, Pulmona | 1989 |
Fatal small-bowel necrosis and pulmonary hypertension in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Humans; Hydralazine; Hypertension, Pulmonary; Hypotension; Infarction; I | 1989 |
[Effect of hydralazine on the pulmonary arterial hypertension in monocrotaline induced cor pulmonale in Macacus rhesus].
Topics: Animals; Arterioles; Hydralazine; Hypertension, Pulmonary; Lung; Macaca mulatta; Monocrotaline; Pulm | 1987 |
Vasodilator therapy in vasoconstrictor-induced pulmonary hypertension in sheep.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Alprostadil; Animals; Disease Mo | 1988 |
Efficacy of vasodilator therapy in canine model of acute pulmonary hypertension.
Topics: Alprostadil; Animals; Coronary Circulation; Disease Models, Animal; Dogs; Female; Heart Ventricles; | 1988 |
Effect of posture, hydralazine, and nifedipine on hemodynamics, ventilation, and gas exchange in patients with chronic obstructive pulmonary disease.
Topics: Carbon Dioxide; Carbon Monoxide; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Lung Di | 1988 |
Pulmonary hypertension in infants with bronchopulmonary dysplasia.
Topics: Bronchopulmonary Dysplasia; Collateral Circulation; Female; Hemodynamics; Humans; Hydralazine; Hyper | 1988 |
Haemodynamic effects of urapidil compared to hydralazine in pulmonary hypertension.
Topics: Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Male; Oxygen; Piperazines | 1986 |
Prostaglandin E1 as a screening vasodilator in primary pulmonary hypertension.
Topics: Adult; Aged; Alprostadil; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Male; | 1987 |
Long-term effects of hydralazine on ventilation and blood gas values in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
Topics: Blood Gas Analysis; Follow-Up Studies; Humans; Hydralazine; Hypertension, Pulmonary; Lung Diseases, | 1987 |
Effects of indomethacin on pulmonary hemodynamics and gas exchange in patients with pulmonary artery hypertension, interference with hydralazine.
Topics: Aged; Cardiac Catheterization; Drug Evaluation; Drug Interactions; Female; Hemodynamics; Humans; Hyd | 1987 |
Pulmonary vascular effects of hydralazine in a canine preparation of pulmonary thromboembolism.
Topics: Animals; Blood Pressure; Cardiac Output; Disease Models, Animal; Dogs; Hemodynamics; Hydralazine; Hy | 1986 |
Danger of vasodilator therapy for pulmonary hypertension in patent foramen ovale.
Topics: Adult; Blood Pressure; Cardiomyopathies; Female; Heart Septum; Humans; Hydralazine; Hypertension, Pu | 1986 |
[Effect of dihydralazine Spofa on precapillary pulmonary hypertension].
Topics: Adult; Dihydralazine; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Male; Midd | 1986 |
Pulmonary hypertension in hydralazine induced systemic lupus erythematosus: association with C4 null allele.
Topics: Alleles; Female; HLA Antigens; HLA-C Antigens; Humans; Hydralazine; Hypertension, Pulmonary; Lupus E | 1986 |
Effects of hydralazine on mouth occlusion pressure and ventilatory response to hypercapnia in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
Topics: Administration, Oral; Cardiac Catheterization; Drug Evaluation; Hemodynamics; Humans; Hydralazine; H | 1987 |
Continuous, low dose of hydralazine, reduces acute hypoxic pulmonary hypertension without a corresponding fall in systemic arterial pressure.
Topics: Animals; Blood Pressure; Female; Hydralazine; Hypertension, Pulmonary; Hypoxia; Male; Sheep | 1986 |
Vasodilators and pulmonary hypertension: where do we go from here?
Topics: Blood Pressure; Humans; Hydralazine; Hypertension, Pulmonary; Piperazines; Pulmonary Circulation; Va | 1987 |
A comparison of the acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension.
Topics: Blood Pressure; Cardiac Output; Epoprostenol; Female; Heart Rate; Hemodynamics; Humans; Hydralazine; | 1985 |
The effects of hydralazine on exercise capacity in pulmonary hypertension secondary to chronic obstructive pulmonary disease.
Topics: Exercise Test; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Lung Diseases, Obstructiv | 1986 |
Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension.
Topics: Adult; Blood Pressure; Cardiac Output; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulm | 1985 |
Hemodynamic effects of vasodilators on pulmonary hypertension in decompensated chronic obstructive pulmonary disease.
Topics: Aged; Blood Pressure; Female; Ferricyanides; Heart Rate; Hemodynamics; Humans; Hydralazine; Hyperten | 1985 |
Hemodynamic effect of hydralazine in interstitial lung disease patients with cor pulmonale. Immediate and short-term evaluation at rest and during exercise.
Topics: Administration, Oral; Adult; Blood Gas Analysis; Drug Administration Schedule; Female; Hemodynamics; | 1985 |
The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension.
Topics: Adolescent; Adult; Child; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Male; | 1985 |
Pulmonary hypertension in systemic lupus erythematosus.
Topics: Adult; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydralazine; Hypertension, Pulmona | 1985 |
The role of vasodilators in patients with progressive systemic sclerosis. Interstitial lung disease and pulmonary hypertension.
Topics: Humans; Hydralazine; Hypertension, Pulmonary; Lung Diseases; Nifedipine; Pulmonary Fibrosis; Sarcoid | 1985 |